Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;103(12):2554-2565.
doi: 10.1111/aogs.14991. Epub 2024 Oct 18.

Chronotypes in middle-aged women with polycystic ovary syndrome: A population-based study

Affiliations

Chronotypes in middle-aged women with polycystic ovary syndrome: A population-based study

Linnea Kroneld et al. Acta Obstet Gynecol Scand. 2024 Dec.

Abstract

Introduction: Circadian rhythm disruption has been associated with the risk of polycystic ovary syndrome (PCOS), as the evening chronotype (EC) shares several traits with PCOS, including metabolic disorders, cardiovascular diseases, and psychiatric disorders. It has been suggested that the biological clock could be targeted with new, preventive, and therapeutic strategies for PCOS in women with biorhythm disorders. We evaluated inner circadian rhythmicity in middle-aged women with PCOS in a population-based setting, focusing on whether women with PCOS and an EC have a specific subtype in relation to their clinical characteristics.

Material and methods: The data derived from the Northern Finland Birth Cohort, a population-based longitudinal birth cohort of 12 058 individuals born in 1966. We compared the circadian phenotype between 314 women with PCOS (according to the Rotterdam criteria) and 1248 women without PCOS at age 46 years using the validated Finnish shortened 6-item Morningness-Eveningness Questionnaire (sMEQ) and the single-item self-assessed morningness-eveningness question.

Results: PCOS was not associated with the EC by the sMEQ (p = 0.495) or self-assessment (p = 0.303). The self-assessed morningness-eveningness values differed from the sMEQ chronotype distribution (p < 0.001), nevertheless, the most frequent chronotype was the intermediate chronotype (IC) determined by both chronotyping methods (sMEQ PCOS 47.7% vs. 45.2% non-PCOS; self-assessment PCOS 66.5% vs. 68.4% non-PCOS). The hyperandrogenic PCOS phenotypes A-C did not differ from the non-hyperandrogenic phenotype D as for the chronotype (p = 0.271). The EC was associated in both groups with depressive and anxiety symptoms (PCOS p = 0.012, non-PCOS p < 0.001) and the use of sleep medication (PCOS p = 0.017, non-PCOS p < 0.001).

Conclusions: The EC was not over-represented in middle-aged women with PCOS or in the hyperandrogenic PCOS phenotypes A-C in our study. This does not support the need for chronotyping in the comprehensive assessment of women with PCOS. However, as chronotypes tend to change with aging, cross-sectional studies in different age groups are warranted to draw conclusions on the role of chronotypes in PCOS and the associated metabolic risks.

Keywords: MEQ; PCOS; chronotype; circadian rhythm; morningness‐eveningness; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart: Formation of PCOS and non‐PCOS groups. AMH, anti‐müllerian hormone; FAI, free androgen index; PCOS, polycystic ovary syndrome.
FIGURE 2
FIGURE 2
Chronotype distribution in women with PCOS and women without PCOS by sMEQ and Self‐assessment. EC, evening chronotype; IC, intermediate chronotype; MC, morning chronotype; PCOS, polycystic ovary syndrome; sMEQ, shortened Morningness‐Eveningness Questionnaire.

Similar articles

References

    1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189:G43‐G64. - PubMed
    1. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova‐Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6‐15. - PubMed
    1. Cinar N, Kizilarslanoglu MC, Harmanci A, et al. Depression, anxiety, and cardiometabolic risk in polycystic ovary syndrome. Hum Reprod. 2011;26:3339‐3345. - PubMed
    1. Pinola P, Puukka K, Piltonen TT, et al. Normo‐ and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertil Steril. 2017;107:788‐795.e2. - PubMed
    1. Kujanpää L, Arffman RK, Pesonen P, et al. Women with polycystic ovary syndrome are burdened with multimorbidity and medication use independent of body mass index at late fertile age: a population‐based cohort study. Acta Obstet Gynecol Scand. 2022;101:728‐736. - PMC - PubMed